Safety and immunogenicity of VCN7-T in infants of 2 and 3 months. Phase I/II. |
Safety and pharmacokinetics of CIGB-552 |
Safety and Pharmacology of CIGB-300 in cervical cancer (CERVIFARM-300 Study) |
Safety assessment of Granulocyte Colony Stimulating Factor:ior LeukoCIM in oncohematologic patients.Phase IV study. |
Safety evaluation of Bacillus clausii AO1125 for its use as a probiotic in humans |
Safety evaluation of Bacillus coagulans AO1167 for its use as a probiotic in humans |
Safety evaluation of Recombinant Human Erythropoietin ior EPOCIM in the treatment of patient with cerebral infarction acute. Study Stage I. |
Safety of Orally Administered Neutral pH Super Oxidation Electrolyzed Solution |
Safety with interferon in skin carcinomas (SCIENCE study) |
Seawater-Rhinitis-Children-Phase III |
Second Line-Acute Asthma |
Sinopharm-SOBERANA COVID-Cienfuegos |
SOBERANA - INTERVENTION |
SOBERANA 01 |
SOBERANA 01A |
SOBERANA 01B |
SOBERANA 02 |
SOBERANA 02-FaseIII |
SOBERANA 02A |
SOBERANA CENTRO |